Skye Bioscience Inc.(US:SKYE) Globenewswire·2025-11-05 12:00Core Viewpoint - Skye Bioscience, Inc. is set to discuss its Q3 2025 financial results and business updates in a conference call on November 10, 2025, following the release of its financial results after market close [1][2] Company Overview - Skye Bioscience is a clinical-stage biotechnology company focused on developing new therapeutic pathways for obesity and metabolic health disorders through next-generation molecules that modulate G-protein coupled receptors [3] - The company is conducting a Phase 2 clinical trial for nimacimab, an antibody that inhibits CB1, and is also assessing its combination with a GLP-1R agonist (Wegovy®) [3] Upcoming Events - A live webcast of the conference call will be available on the Skye Investor Relations website, along with the earnings press release and financial tables [2] - Skye will present at the Stifel 2025 Healthcare Conference in New York on November 13, 2025, and will be available for one-on-one meetings [2]